NCCapital

Eli Lilly is continuing its aggressive acquisition spree, announcing Monday that it will acquire privately held biotech company Merida Biosciences for up to $2.875 billion. The deal gives Lilly access to a promising platform aimed at treating serious autoimmune and allergic diseases as the pharmaceutical giant works to diversify beyond its blockbuster weight-loss and diabetes businesses.

The transaction will bring Merida's precision antibody-degradation technology into Lilly's growing immunology portfolio. Rather than broadly suppressing the immune system, Merida's approach is designed to selectively remove disease-causing antibodies while preserving normal immune function.

Merida's lead program, MER511, is currently in Phase 1 development for Graves' disease and thyroid eye disease, or TED. The experimental treatment is designed to target the autoantibodies that drive these conditions, potentially addressing the underlying cause of the diseases rather than simply treating their downstream effects.

Early clinical data have given Lilly reason to be interested. Initial Phase 1 results showed substantial reductions in pathogenic thyroid-stimulating antibodies, along with what the companies described as a favorable early safety profile. The program remains experimental, however, and will need to demonstrate its effectiveness and safety in larger clinical trials.

Merida's pipeline extends beyond Graves' disease and thyroid eye disease. The company is also developing MER769, a preclinical program targeting antibody-driven allergic conditions including food allergies, asthma, and chronic spontaneous urticaria. Earlier-stage programs are also focused on kidney diseases and other immune-mediated conditions.

The acquisition represents another step in Lilly's effort to reduce its dependence on the enormous success of its obesity and diabetes franchises. Drugs such as Mounjaro and Zepbound have generated massive demand, providing Lilly with the financial resources to pursue additional businesses and replenish its pipeline through acquisitions.

Lilly has been on an extraordinary deal-making run throughout 2026. The Merida transaction follows acquisitions and agreements involving companies across areas including mental health, vaccines, cancer, genetic medicine, and other fields. Recent deals include the planned acquisition of AtaiBeckley and several other biotech companies, pushing Lilly's total announced deal spending well into the tens of billions of dollars.

The structure of the Merida transaction also gives Lilly some protection against the risks of acquiring an early-stage biotech. The $2.875 billion price includes an upfront payment as well as additional milestone payments, meaning a portion of the consideration is contingent on the development and progress of Merida's programs.

For Lilly, the appeal is ultimately the possibility of creating a new class of treatments for diseases where existing therapies do not directly eliminate the antibodies responsible for the underlying condition. The company believes Merida's platform could potentially be applied across a much broader range of autoimmune and allergic diseases if the technology continues to deliver positive clinical results.

The acquisition is expected to close during the fourth quarter of 2026, subject to regulatory approvals and other customary closing conditions. If successful, the deal would give Lilly another potentially valuable pipeline of treatments while reinforcing the pharmaceutical giant's broader strategy: use the enormous cash generation from its weight-loss franchise to build a more diversified drug business for the years ahead.